Author Archives: Jennifer Boggs

Mystic moldy pizza: Food for thought from Allicense 2014

SAN FRANCISCO – When talking trends in biopharma there’s no shortage of metaphors – Tuesday’s health care debate, for example, went for the timely baseball terms, referencing singles and home runs – or oft-overused industry buzzwords, of which the recent…

Share

Rock to the left, hard place to the right: One dilemma of compassionate use

Before its unfortunate drop in quality in its last few seasons, the medical drama House was one of my favorite shows, with its title character, a cranky, possibly drug-addicted doctor solving diagnostic riddles and saving lives with Sherlockian brilliance, and quite…

Share

Drug pricing: Are we paying for efficacy or innovation?

What if we paid professional athletes only when they won? What if spectators got their tickets refunded whenever the home team lost? That might make that $1,300 Super Bowl ticket a little easier to purchase. And, hey, perhaps that might…

Share

‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’

We at BioWorld actually contemplated putting out a zany blog about biotech to commemorate April Fools’ Day – i.e. biotech firm develops drug for childhood cooties, or something equally ridiculous – but, in the end, we decided to pass. And…

Share

Big Wins, a Cliff, a Race and a Red Face: A 2012 Recap

Now that 2012 is drawing to a close, it’s once again time to take a look back at a year that saw some big hits and misses for the biotech industry – and there were plenty of both. The hits…

Share

#BIO2012: Tips for a Wicked Good Meeting

Heading to Boston next week for the 2012 Biotechnology Industry Organization International convention? So are we. In fact, BioWorld has attended and exhibited at the annual BIO meeting for 18 years, so we know a thing or two about navigating…

Share

Profit vs. Value: When Activist Shareholders Attack

Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…

Share

The Good, the Bad and . . . the Huh? A 2011 Biotech Recap

The past year brought the biotech sector a mixed bag of news. Some of it was positive – for instance, the FDA picked up its drug approval pace in 2011 and, in some cases, even surprised the most hardened biotech…

Share

Reason Free from Passion? That’s Not Biotech

SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs…

Share

What’s in a Biotech Name? It’s Greek to Me

OK, you’re a biotech entrepreneur and you’ve found some interesting new technology. You’ve secured some seed funding, found some lab space and filled out all the appropriate paperwork for a business license. All’s that left to incorporate your brand new…

Share